DYN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DYN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Dyne Therapeutics's Other Operating Expense for the three months ended in Sep. 2024 was $0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.
Dyne Therapeutics's quarterly Other Operating Expense increased from Mar. 2024 ($-0.00 Mil) to Jun. 2024 ($0.00 Mil) and increased from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.00 Mil).
Dyne Therapeutics's annual Other Operating Expense declined from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($-0.00 Mil) but then increased from Dec. 2022 ($-0.00 Mil) to Dec. 2023 ($0.00 Mil).
The historical data trend for Dyne Therapeutics's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dyne Therapeutics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Other Operating Expense | Get a 7-Day Free Trial | - | - | - | - | - |
Dyne Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Other Operating Expense | Get a 7-Day Free Trial | - | - | - | - | - |
GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Dyne Therapeutics's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.
Dirk Kersten | director, 10 percent owner | C/O FORBION CAPITAL FUND IV COOPERATIEF, GOOMIER 2-35, NAARDEN P7 14111 DC |
Richard William Scalzo | officer: See Remarks | 25 ALBERTA LANE, HOLLISTON MA 01746 |
Carlo Incerti | director | FORBION CAPITAL FUND IV COOPERAITEF U.A., GOOMIER 2-35, NAARDEN P7 1411DC |
Oxana Beskrovnaya | officer: See Remarks | C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451 |
Jason P Rhodes | director, 10 percent owner | C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139 |
Susanna Gatti High | officer: Chief Operating Officer | 75 LORIMER ROAD, BELMONT MA 02141 |
Wildon Farwell | officer: Chief Medical Officer | C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET MA 02451 |
Jonathan Mcneill | officer: See Remarks | C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451 |
Joshua T Brumm | director, officer: See Remarks | ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588 |
Atlas Venture Opportunity Fund I, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Atlas Venture Fund Xi, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Atlas Venture Associates Opportunity Ii, Lp | 10 percent owner | 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
Atlas Venture Opportunity Fund Ii, L.p. | 10 percent owner | 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
Atlas Venture Associates Opportunity Ii, Llc | 10 percent owner | 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
Romesh Subramanian | 10 percent owner, officer: Chief Scientific Officer | C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451 |
From GuruFocus
By GuruFocus News • 11-15-2024
By GuruFocus News • 11-04-2024
By GuruFocus News • 11-14-2024
By Marketwired • 09-17-2024
By PRNewswire • 10-03-2024
By Business Wire • 09-16-2024
By Marketwired • 09-23-2024
By GuruFocus News • 11-14-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.